Eli Lilly announced on Monday its agreement to acquire the biotechnology company Kelonia Therapeutics in a deal valued at up to $7 billion. The acquisition aims to bolster Lilly's position in the hematology sector with advanced cancer treatment technology.
Deal Structure and Timeline
The financial terms of the acquisition are structured as follows:
- Upfront Payment: Lilly will pay $3.25 billion immediately.
- Contingent Payments: Remaining payments are dependent on achieving specific clinical, regulatory, and commercial milestones.
- Expected Close Date: The transaction is anticipated to finalize in the second half of 2026.
Kelonia's Technology: In Vivo CAR-T Therapy
Kelonia specializes in developing technology for in vivo CAR-T therapy. This advanced treatment method reprograms a patient's T-cells directly inside the body to target and attack cancer.
This represents a significant advancement over current methods:
- Traditional Approach (Ex Vivo): Current treatments require an ex vivo process, which involves harvesting cells, engineering them in a laboratory setting, and then reintroducing them to the patient. This process is noted as being logistically intensive.
- Kelonia's Advantage: The in vivo therapy, described by Lilly's oncology president, Jacob Van Naarden, is an intravenously delivered, one-time treatment. It targets the body's T-cells, transforming them to fight cancer without requiring preconditioning.
Strategic Implications for Lilly
Lilly's leadership views this acquisition as a major strategic move to expand its portfolio in hematology. According to Van Naarden, the technology offers a broadly applicable medicine, unlike personalized cell therapies that are often restricted to specialized academic medical centers.
This move places Lilly in a more competitive position within the oncology space, especially when considering recent industry activity:
- Johnson & Johnson's CAR-T treatment, Carvykti, generated $1.89 billion in sales last year for multiple myeloma.
- Gilead recently acquired Arcellx, a rival to J&J's drug, for $7.8 billion.
